This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 17, 2013 /PRNewswire/ --
Frederick R. Appelbaum, M.D., a world expert in the research and treatment of blood cancers who for the past two decades has served as senior vice president and director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, has been named executive vice president and deputy director of Fred Hutch. His appointment is effective immediately.
"We are all delighted that Fred, who has essentially lived his life at the Hutch, will now devote his energies and experience to telling our story to the world outside our walls," said
Lawrence Corey, M.D., president and director of Fred Hutch. "Fred's experience, together with his vast knowledge of science and the history of the Hutch, will be invaluable in developing the community relationships and programs that we and our clinical partner, the
Seattle Cancer Care Alliance, need for continued growth and impact."
While he will continue to conduct research, in his new role representing the Hutch Appelbaum will lead the institution's strategic research partnerships. "Fred is already an international figure in oncology, and he will devote more time to working with the National Cancer Institute and other federal agencies," Corey said.
As deputy director Appelbaum also will focus on maintaining the fiscal health of Fred Hutch through sustained federal funding and other revenue sources, including philanthropy and technology transfer.
"The mission of Fred Hutch is to eliminate cancer as a cause of suffering and death. If we are going to be successful in that effort, we need continued resources, and helping to ensure that will be a big part of my new role," Appelbaum said.
One such example is working with the NIH and National Cancer Institute to secure continuous renewal of the
Cancer Center Support Grant, which funds the infrastructure of the
Fred Hutchinson/University of Washington Cancer Consortium, one of 41 NCI-designated Comprehensive Cancer Centers nationwide. Other initiatives involve the interaction of the Hutch with its partners in support of initiatives such as a joint UW/Fred Hutch program in cancer molecular diagnostics currently under development.
"My new role will allow me to focus more specifically on the implementation of these key scientific strategies and partnerships. I truly believe that these initiatives will have a profound and lasting impact on the future of Fred Hutch," he said.